参考文献/References:
［1］Ward MM,Deodhar A,Gensler LS,et al.2019 update of the American college of rheumatology/spondylitis association of America/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis［J］.Arthritis Care & Research,2019,71(10):1285-1299.
［2］中华医学会风湿病学分会.成人斯蒂尔病诊断及治疗指南［J］.中华风湿病学杂志,2010,14(7):487-489.
［3］Maksymowych WP.Disease modification in ankylosing spondylitis［J］.Nature Reviews Rheumatology,2010,6(2):75-81.
［4］Ward MM,Kuzis S.Medication toxicity among patients with ankylosing spondylitis［J］.Arthritis and Rheumatism,2002,47(3):234-241.
［5］李彦,孟祥震.强直性脊柱炎的中医溯源考析［J］.浙江中医杂志,2021,56(4):297-299.
［6］陈松,袁普卫,李堪印.李堪印治疗强直性脊柱炎“三期辨证”思想［J］.辽宁中医杂志,2019,46(10):2054-2056.
［7］熊曼琪.伤寒论［M］.北京:人民卫生出版社,2000.
［8］高志刚,戴卫红.芍药甘草汤的临床应用及方剂研究进展［J］.河北中医,2019,41(5):792-796.
［9］杨旭,王景霞,张建军,等.芍药甘草汤对中枢性肌张力增高大鼠解痉止痛最佳配比的筛选研究［J］.北京中医药大学学报,2015,38(1):33-36.
［10］袁奕清,胡小军.芍药甘草汤加减对急性胃溃疡患者血清炎症因子、胃黏膜表皮生长因子及受体表达的影响［J］.世界中西医结合杂志,2021,16(1):92-95,99.
［11］陆星宇,任雁威,杨雪,等.芍药甘草汤加减治疗带状疱疹后遗神经痛对患者疼痛及血清NPY、SP水平的影响［J］.海南医学,2021,32(1):31-34.
［12］任东坡,唐欣荣,吕发明.加味芍药甘草汤对大鼠跟腱末端病影响的实验研究［J］.河南中医,2009,29(5):455-457.
［13］何玉敏,王进燕,何冰杰,等.芍药甘草汤对呼吸道合胞病毒诱发哮喘急性加重小鼠相关炎症因子、Bcl-2和Bax表达及免疫功能的影响［J］.中国中医急症,2020,29(6):1031-1034,1054.
［14］曲缘章,马生军,朱广伟,等.芍药甘草汤的历史沿革与现代研究［J］.中国实验方剂学杂志,2020,26(6):216-225.
［15］程青青,李炜,程鹏,等.乌头汤治疗肾虚督寒型强直性脊柱炎30例临床观察［J］.风湿病与关节炎,2021,10(2):5-7,27.
［16］陆莉君.独活寄生汤治疗强直性脊柱炎临床观察［J］.光明中医,2021,36(5):772-774.
［17］世界中医药学会联合会.网络药理学评价方法指南［J］.世界中医药,2021,16(4):527-532.
［18］庄延双,蔡宝昌,张自力.网络药理学在中药研究中的应用进展［J］.南京中医药大学学报,2021,37(1):156-160.
［19］汝锦龙.中药系统药理学数据库和分析平台的构建和应用［D］.杨凌：西北农林科技大学,2015.
［20］Devi KP,Malar DS,Nabavi SF,et al.Kaempferol and inflammation:from chemistry to medicine［J］.Pharmacological Research,2015,99:1-10.
［21］Alam W,Khan H,Shah MA,et al.Kaempferol as a dietary anti-inflammatory agent:current therapeutic standing［J］.Molecules (Basel,Switzerland),2020,25(18):4073.
［22］Hosseinpour-Niazi S,Mirmiran P,Fallah-Ghohroudi A,et al.Non-soya legume-based therapeutic lifestyle change diet reduces inflammatory status in diabetic patients:a randomised cross-over clinical trial［J］.The British Journal of Nutrition,2015,114(2):213-219.
［23］Carullo G,Cappello AR,Frattaruolo L,et al.Quercetin and derivatives:useful tools in inflammation and pain management［J］.Future Medicinal Chemistry,2017,9(1):79-93.
［24］Carrasco-Pozo C,Castillo RL,Beltrán C,et al.Molecular mechanisms of gastrointestinal protection by quercetin against indomethacin-induced damage:role of NF-κB and Nrf2［J］.The Journal of Nutritional Biochemistry,2016,27:289-298.
［25］Magrey MN,Khan MA.The paradox of bone formation and bone loss in ankylosing spondylitis:evolving new concepts of bone formation and future trends in management［J］.Current Rheumatology Reports,2017,19(4):17.
［26］Franois RJ,Neure L,Sieper J,et al.Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis:detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases［J］.Annals of the Rheumatic Diseases,2006,65(6):713-720.
［27］Rocha FAC,Pinto ACMD,Lopes JR,et al.Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis-time to reconsider treatment guidelines?A case series and review of literature［J］.Clinical Rheumatology,2021,40(5):1881-1887.
［28］刘小莉,张红梅,唐敏,等.不同疾病分期强直性脊柱炎患者外周血DKK-1、MMP-3、TNF-α和IL-6的表达及治疗前后水平变化［J］.现代免疫学,2020,40(4):300-305.
［29］Suzuki T,Yoshinaga N,Tanabe S.Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium［J］.The Journal of Biological Chemistry,2011,286(36):31263-31271.
［30］Tarner IH,Müller-Ladner U,Uhlemann C,et al.The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha,IL-1beta,and IL-6 in patients with ankylosing spondylitis［J］.Clinical Rheumatology,2009,28(4):397-402.
［31］Zhong XF,Wang BN,Zhang G,et al.Autophagy activation is involved in acidic fibroblast growth factor ameliorating Parkinson's disease via regulating tribbles homologue 3［J］.Frontiers in Pharmacology,2019,10:1428.
［32］Morita I.Distinct functions of COX-1 and COX-2［J］.Prostaglandins & Other Lipid Mediators,2002,68/69:165-175.
［33］Jafarnezhad-Ansariha F,Yekaninejad MS,Jamshidi AR,et al.The effects of β-D-mannuronic acid (M2000),as a novel NSAID,on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte/macrophage,J774 cell line［J］.Inflammopharmacology,2018,26(2):375-384.
［34］Song XY,Qian YC.IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases［J］.Cellular Signalling,2013,25(12):2335-2347.
［35］Gracey E,Yao YC,Qaiyum Z,et al.Altered cytotoxicity profile of CD8+ T cells in ankylosing spondylitis［J］.Arthritis & Rheumatology (Hoboken,N J),2020,72(3):428-434.
［36］Rezaiemanesh A,Abdolmaleki M,Abdolmohammadi K,et al.Immune cells involved in the pathogenesis of ankylosing spondylitis［J］.Biomedicine & Pharmacotherapy,2018,100:198-204.
［37］Ciccia F,Guggino G,Rizzo A,et al.Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut,in the peripheral blood,synovial fluid and bone marrow of patients with ankylosing spondylitis［J］.Annals of the Rheumatic Diseases,2015,74(9):1739-1747.
［38］Ebihara S,Date F,Dong YP,et al.Interleukin-17 is a critical target for the treatment of ankylosing enthesitis and psoriasis-like dermatitis in mice［J］.Autoimmunity,2015,48(4):259-266.
［39］Korn T,Bettelli E,Oukka M,et al.IL-17 and Th17 cells［J］.Annual Review of Immunology,2009,27:485-517.
［40］Miossec P,Kolls JK.Targeting IL-17 and TH17 cells in chronic inflammation［J］.Nature Reviews Drug Discovery,2012,11(10):763-776.
［41］Gravallese EM,Schett G.Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis［J］.Nature Reviews Rheumatology,2018,14(11):631-640.